Clinical Trial Update: Evaluate Bioequivalence of Micafungin (50mg/Vial) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating bioequivalence of micafungin 50 mg/vial in invasive candidiasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Candidiasis

Drugs mentioned

• Micafungin (micafungin)

Snippet

Sponsor: Yung Shin Pharm. Ind. Co., Ltd. | Conditions: Invasive Candidiasis | Phase 4 | Status: COMPLETED